SCHEMBL16644171

SCHEMBL16644171

Cc1cnc(-n2cc(-c3ccc(N)nc3)c(C)n2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
PIK3CD O00329 2/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
NOS1 P29475 1/20 0.33
PI4KB Q9UBF8 6/20 0.33
CYP3A4 P08684 3/20 0.33
KIT P10721 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16644112 0.81 KDM4E (0.34) KDM4EALDH1A1GAAPIK3CDMKNK1
SCHEMBL20936832 0.74 ALDH1A1 (0.44) ALDH1A1PIK3CDMKNK1MKNK2NOS3
SCHEMBL16644130 0.73 ADORA1 (0.44) ADORA3ADORA1
SCHEMBL16636525 0.72 IL2 (0.46) KDM4EALDH1A1GAAMEN1NPC1
SCHEMBL16644138 0.72 TDO2 (0.42) PIK3CDMTORPIK3CA
SCHEMBL16636881 0.71 IL2 (0.38) KDM4EALDH1A1GAANPC1RAB9A
SCHEMBL16644231 0.69 NOS1 (0.34) ALDH1A1NOS1
SCHEMBL19521404 0.68 KDM4E (0.38) KDM4EALDH1A1PIK3CDCYP3A4MAP4K4
SCHEMBL10053498 0.68 ALDH1A1 (0.55) KDM4EALDH1A1GAAPIK3CDMKNK1
SCHEMBL16644144 0.66 PTK2 (0.33) KDM4EALDH1A1GAAADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9611263-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2017-04-04 US disclosed
US-9611263-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2017-04-04 US disclosed
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2016-08-11 US disclosed
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2016-08-11 US disclosed
WO-2015054283-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229845-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 KDM4E 4057/4885ALDH1A1 4409/4885GAA 994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.